Literature DB >> 14607201

Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol.

Savina Nodari1, Marco Metra, Livio Dei Cas.   

Abstract

We compared the effects of 6 months administration of atenolol or nebivolol on resting and exercise hemodynamic parameters and maximal exercise capacity, in 26 patients with hypertension and left ventricular (LV) diastolic dysfunction (ejection fraction >50%, end-diastolic diameter <60 mm and increased pulmonary wedge pressure at rest and/or at peak exercise). Both atenolol and nebivolol administration was associated with a significant decrease in the resting and peak exercise heart rate and blood pressure and in LV mass, with an increase in the E/A ratio. This latter effect was greater with nebivolol. Nebivolol was associated with an increase in the peak VO(2), VO(2) at the anaerobic threshold and with a decrease in the VE/VCO(2) ratio. With regards to the hemodynamic parameters, compared to patients on atenolol, those on nebivolol showed a lower reduction in the cardiac index, a greater increase in the stroke volume index and a decline in the mean pulmonary artery pressure and pulmonary wedge pressure, both at rest and peak exercise. Thus, although the two beta-blockers have a similar antihypertensive action, nebivolol administration was associated with a greater hemodynamic improvement, compared to atenolol.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14607201     DOI: 10.1016/s1388-9842(03)00054-0

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  42 in total

1.  Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat.

Authors:  Xinli Zhou; Lixin Ma; Javad Habibi; Adam Whaley-Connell; Melvin R Hayden; Roger D Tilmon; Ashley N Brown; Jeong-A Kim; Vincent G Demarco; James R Sowers
Journal:  Hypertension       Date:  2010-02-22       Impact factor: 10.190

Review 2.  New drugs for hypertension: what do they offer?

Authors:  Alan H Gradman; Yoel Vivas
Journal:  Curr Hypertens Rep       Date:  2006-10       Impact factor: 5.369

3.  Alterations in endothelial control of the pulmonary circulation in exercising swine with secondary pulmonary hypertension after myocardial infarction.

Authors:  Daphne Merkus; Birgit Houweling; Vincent J de Beer; Zaida Everon; Dirk J Duncker
Journal:  J Physiol       Date:  2007-02-08       Impact factor: 5.182

4.  Circulation time measurement from sleep studies in patients with obstructive sleep apnea.

Authors:  Younghoon Kwon; Talha Khan; Marc Pritzker; Conrad Iber
Journal:  J Clin Sleep Med       Date:  2014-07-15       Impact factor: 4.062

5.  Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat.

Authors:  Lixin Ma; Rukhsana Gul; Javad Habibi; Ming Yang; Lakshmi Pulakat; Adam Whaley-Connell; Carlos M Ferrario; James R Sowers
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

Review 6.  Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?

Authors:  Gerard O Oghlakian; Ilke Sipahi; James C Fang
Journal:  Mayo Clin Proc       Date:  2011-05-16       Impact factor: 7.616

Review 7.  Antihypertensive drugs and the heart.

Authors:  Joseph A Diamond; Robert A Phillips
Journal:  Curr Cardiol Rep       Date:  2004-11       Impact factor: 2.931

8.  β-Blockers are associated with a reduction in COPD exacerbations.

Authors:  Surya P Bhatt; James M Wells; Gregory L Kinney; George R Washko; Matthew Budoff; Young-Il Kim; William C Bailey; Hrudaya Nath; John E Hokanson; Edwin K Silverman; James Crapo; Mark T Dransfield
Journal:  Thorax       Date:  2015-08-17       Impact factor: 9.139

9.  Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLC.

Authors:  S U Kokil; M S Bhatia
Journal:  Indian J Pharm Sci       Date:  2009-03       Impact factor: 0.975

Review 10.  Hypertension and diastolic heart failure.

Authors:  Alan H Gradman; J Travis Wilson
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.